How I treat high-risk multiple myeloma
The treatment paradigms for multiple myeloma and amyloidosis have been transformed by novel therapies and continue to be modified in the face of new immunologic
Related Articles
HCA reports almost $1 billion more in charity care to Medicare than to its shareholders, drawing more taxpayer money
HCA Healthcare, the country’s biggest hospital chain, reported almost $1 billion more in charity care to CMS than in its financial statement, drawing more taxpayer…
Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer
A novel urine biomarker test may help reduce the number of cystoscopies necessary in high-risk patients with bladder cancer, according to findings presented at the…
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectini…
Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer
A novel urine biomarker test may help reduce the number of cystoscopies necessary in high-risk patients with bladder cancer, according to findings presented at the…
Anti-EGFR Rechallenge in Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer
This nonrandomized controlled trial evaluates anti–epidermal growth factor receptor (EGFR) rechallenge therapy in patients in Italy with circulating tumor DNA (ctDNA) RAS/BRAF wild-type (wt) metastatic…
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectini…
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectini…
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectini…
Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non–small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectini…
How I treat adult T-cell leukemia/lymphoma
Cook and Phillips provide their expert views on how to treat patients with adult T-cell leukemia/lymphoma (ATL), an uncommon complication of long-term infe